Australia's Radiopharm Theranostics jumps on FDA's Fast Track Designation for product

Radiopharm Theranostics

11/06/2025 03:26

** Shares of Radiopharm Theranostics RAD.AX rise 12.5% to A$0.027, their biggest intraday pct gain since June 2

** The radiotherapeutics co receives U.S. Food and Drug Administration's (FDA) Fast Track Designation for its RAD101 product used in treatment of brain metastases

** FDA's Fast Track Designation grants help in expediting the process of product review

** Stock marks its highest level in a week

** About 2.5 mln shares change hands, 1x the 30-day average

** Stock up 8.3% YTD, including moves in current session

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)

 ((JasmeenAraIslam.Shaikh@thomsonreuters.com;))